Novo Nordisk says new strategy targets come Sept 21, not at Sept 15 staff meeting

Novo Nordisk expects to introduce new Strategic Aspirations at its Capital Markets Day on Sept 21, 2026, the company said in its 2025 annual report ^[1]. A separate internal employee townhall on Sept 15 is not that event. Bloomberg reported on Sept 11 that Novo invited staff to a Tuesday afternoon meeting to "share an exciting update about our company's next chapter," and that a company spokesperson confirmed the internal event was scheduled ahead of the capital markets day on Sept 21 ^[2].

As of mid-September, Novo had not disclosed what the new strategy contains, what financial targets it sets, or whether it includes new commitments in the obesity market ^[1][2]. The current Strategic Aspirations were introduced in 2019 and are set to conclude this year ^[1]. Under them, Novo said sales more than doubled to DKK 309 billion in 2025 at a compound annual growth rate of 17%, while operating profit more than doubled to DKK 128 billion at a 16% CAGR ^[1]. Obesity care sales rose from DKK 6 billion in 2019 to DKK 82 billion in 2025 ^[1].

The 2025 results, reported Feb 3, 2026, give the backdrop for the Sept 21 update. Net sales rose 6% in Danish kroner and 10% at constant exchange rates to DKK 309.1 billion, while operating profit fell 1% in kroner and rose 6% at constant exchange rates to DKK 127.7 billion ^[1]. Novo said that without about DKK 8 billion in company-wide transformation costs, operating profit would have risen 6% in kroner and 13% at constant exchange rates ^[1]. Obesity care sales increased 31% at constant exchange rates to DKK 82.3 billion, and diabetes value market share slipped 3.6 percentage points to 30.1% ^[1]. The company said it provided medical treatment to 42.0 million people with diabetes and 3.6 million people with obesity, and reached nearly 46 million people overall ^[1].

For 2026, Novo projected adjusted sales growth of -5% to -13% at constant exchange rates and adjusted operating profit growth of the same range, with results helped by a reversal of USD 4.2 billion in US 340B drug pricing rebate provisions ^[1]. The company said the outlook reflects lower realized prices, including effects tied to the US "Most Favoured Nations" agreement, semaglutide patent expiry in certain international markets and competition ^[1]. Chief executive Mike Doustdar said: "In 2026, Novo Nordisk will face pricing headwinds in an increasingly competitive market" ^[1].

On the product side, the US Food and Drug Administration approved once-daily oral semaglutide 25 mg for obesity under the brand name Wegovy pill on Dec 22, and Novo launched it Jan 5, 2026 ^[1]. As of Jan 23, weekly prescriptions totaled about 50,000, with uptake mainly driven by the 1.5 mg starter dose in the self-pay channel ^[1]. Novo has also submitted semaglutide 7.2 mg and CagriSema to the FDA ^[1].

Why it matters for patients

The Sept 15 employee meeting is internal. Any change in how Novo positions Ozempic, Wegovy or its pipeline for the US market would come from the Sept 21 investor event, and none of those details had been disclosed as of mid-September ^[1][2].

Two signals in the company's own reporting matter for people paying for these drugs. Novo attributes its weaker 2026 sales outlook partly to lower realized prices and to the US "Most Favoured Nations" agreement ^[1]. Realized prices are what the manufacturer nets after rebates and discounts; the sources do not say how that translates into list prices, insurance coverage or out-of-pocket costs for patients ^[1]. Separately, Novo said early Wegovy pill uptake is concentrated in the self-pay channel and the 1.5 mg starter dose ^[1], which indicates some patients are paying without insurance for the oral version, though no price figures were disclosed.

What happens next

Sept 21, 2026 is the date Novo has given for the Capital Markets Day where it expects to introduce new Strategic Aspirations ^[1]. The company has not said whether that event will include new obesity-market commitments or financial targets beyond the aspirations themselves ^[1][2].

Doustdar said Novo looks forward this year to regulatory decisions for Mim8 in hemophilia and CagriSema in obesity, plus phase 3 readouts for etavopivat and ziltivekimab ^[1]. Specific decision dates have not been disclosed.